Early detection Target healthcare providers and research sponsors focusing on early diagnosis of neurodegenerative disorders. Neurosteer’s real-time EEG analytics and 100+ decomposed components offer objective biomarkers for Parkinson’s, Alzheimer’s, dementia, and epilepsy, presenting opportunities with neurology clinics, specialty centers, and trial sites seeking earlier intervention.

Clinical trial fit Position as a companion monitoring and biomarker platform for neurology clinical trials. The cloud-based real-time monitoring, objective biomarkers, and continuous patient data can improve trial endpoints, patient stratification, and drug/stimulation optimization, appealing to CROs and biopharma running CNS studies.

Affordability edge Emphasize cost-efficient screening and remote monitoring capabilities to reduce in-hospital visits and long-term care costs. The wearable and cloud solution can enable scalable screening programs and remote patient management, appealing to hospitals, clinics, and accountable care organizations seeking to optimize spend.

Strategic partnerships Leverage past awards and speaking engagements to build credibility with potential resellers, distributors, and integrators in medical device ecosystems. Target neurotech hubs, AI + neurotech conferences, and university hospital networks for co-marketing and joint deployments.

Health-tech expand Cross-sell to adjacent neurodiagnostic and neuromodulation markets by highlighting compatibility with neurostimulation and precision drug selection workflows. Engage equipment integrators, EMR/EHR platforms, and telehealth vendors to broaden adoption beyond standalone wearables into comprehensive care pipelines.